Gilead, Cognizant
Cognizant Expands Partnership with Gilead
Gilead is expected to enhance its efficiency through leveraging Cognizant’s expertise in AI and advanced technology applications. By deploying these solutions across the value chain, Cognizant aims to help Gilead achieve significant benefits through a newly optimized financial framework.
In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of ...
Gilead Sciences Inc. must face a fired employee’s lawsuit alleging its response to a co-worker’s false sexual harassment ...
Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...
Gilead Sciences Inc. closed 3.35% below its 52-week high of $98.90, which the company achieved on November 11th.
Cognizant (CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (GILD) that aims to ...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...
The stock's fall snapped a two-day winning streak.
Zacks.com on MSN2d
Gilead Sciences (GILD) Stock Dips While Market Gains: Key FactsIn the most recent trading session, Gilead Sciences (GILD) closed at $93.85, indicating a -1.57% shift from the previous trading day.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback